The Boston Elbow

November 1984

NTIS order #PB85-145936

## The Boston Elbow

NOVEMBER 1984

This is an O

reviewed nor approved Board



# HEALTH TECHNOLOGY CASE STUDY 29 The Boston Elbow

NOVEMBER 1984

This case study was performed as part of OTA's Assessment of

Federal Policies and the Medical Devices Industry

Prepared for OTA by: Sandra J. Tanenbaum, Ph.D. Health Policy Center Brandeis University

OTA Case Studies are documents containing information on a specific medical technology or area of application that supplements formal OTA assessments. The material is not normally of as immediate policy interest as that in an OTA Report, nor does it present options for Congress to consider.



CONGRESS OF THE UNITED STATES Office of Technology Assessment Washington D C 20510 Recommended Citation:

Tanenbaum, Sandra J., The Boston Elbow (Health Technology Case Study 29), OTA-HCS-29, Washington, DC: U.S. Congress, Office of Technology Assessment, November 1984, This case study was performed as part of OTA's assessment of Federal Policies and the Medical Devices Industry.

Library of Congress Catalog Card Number 84-601139

For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, DC 20402

## Preface

The Boston Elbow is Case Study 29 in OTA's Health Technology Case Study Series. This case study has been prepared in connection with OTA's project on *Federal Policies and the Medical Devices Industry*, which was requested by the Senate Committee on Labor and Human Resources and endorsed by the Senate Committee on Veterans' Affairs. A listing of other case studies in the series is included at the end of this preface.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA's overall project on The Implications of Cost-Effectiveness Analysis of Medical Technology. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in various fields. Selection criteria were developed to ensure that case studies provide the following:

• examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);

- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e. g., cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies are either prepared by OTA staff, commissioned by OTA and performed under contract by experts (generally in academia), or written by OTA staff on the basis of contractors' papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, comments are provided to authors, along with OTA's suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least 30 reviewers, and sometimes by 80 or more outside reviewers. These individuals may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA's concern with each case study's scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.

Case Study Series	Case study title; author(s);	Seri	· · · · · · · · · · · · · · · · · · ·
number	OTA publication number <sup>b</sup>	nun	mber OTA publication number <sup>b</sup>
Renal Dis	analysis, Policy Formulation, and End-Stage sease; d A. Rettig (OTA-BP-H-9 (l))°		Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew
2 The Fease Diagnost	ibility of Economic Evaluation of ic Procedures: The Case of CT Scanning; L. Wagner (OTA-BP-H-9(2))	15	(OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins
3 Screening Assessme	g for Colon Cancer: A Technology nt;		Noralou Roos, and John P. Bunker (OTA-BP-H-9(15))
4 Cost Effe	M. Eddy (OTA-BP-H-9(3)) ctiveness of Automated Multichannel y Analyzers;	16	The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-Bp-H-9(16))
Milton (OTA-1	C. Weinstein and Laurie A. Peadman BP-H-9(4))	17	Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhause
Costs of	al Disease: Assessing the Effectiveness and the Keyes Technique; d M. Scheffler and Sheldon Rovin	18	(OTA-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy;
(OTA-l 6 The Cost	BP-H-9(5)) Effectiveness of Bone Marrow Transplant		Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9 (18)) <sup>d</sup>
Stuart	and Its Policy Implications; O. Schweitzer and C. C. Scalzi Bp-H-9(6))	19 20	Assessment of Four Common X-Ray Procedures; Judith L. Wagner (OTA-BP-H-9(19))° Mandatory Passive Restraint Systems in
7 Allocating	g Costs and Benefits in Disease Prevention s: An Application to Cervical Cancer	20	Automobiles: Issues and Evidence; Kenneth E. Warner (OTA-Bp-H-15(20)) <sup>r</sup>
Screening Bryan		21	
Endoscop	Effectiveness of Upper Gastrointestinal y; an A. Showstack and Steven A. Schroeder	22	(OTA-BP-H-16 (21))g
(OTA-l 9 The Artif	BP-H-9(8)) ficial Heart: Cost, Risks, and Benefits;		Leonard Saxe, Denise Dougherty, Katharine Esty and Michelle Fine (OTA-HCS-22)
(OTA-I	ah P. Lubeck and John P. Bunker 3P-H-9(9)) s and Effectiveness of Neonatal Intensive	23	The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis; John C. Langenbrunner (Office of Technology
Care; Peter H	Budetti, Peggy McManus, Nancy Barrand,	24	Assessment) (OTA-HCS-23) Variation in Length of Hospital Stay: Their
1 Benefit a	Ann Heinen (OTA-BP-H-9 (1 O)) nd Cost Analysis of Medical Interventions: of Cimetidine and Peptic Ulcer Disease;	25	Relationship to Health Outcomes; Mark R. Chassin (OTA-HCS-24) Technology and Learning Disabilities;
Harvey (OTA-I	v V. Fineberg and Laurie A. Pearlman BP-H-9(11))	26	Candis Cousins and Leonard Duhl (OTA-HCS-2 Assistive Devices for Severe Speech Impairments;
	Selected Respiratory Therapy Modalities: nd Relative Costs in the Washington, D.C.	27	Judith Randal (Office of Technology Assessment (OT'A-I-icS-26) Nuclear Magnetic Resonance Imaging Technology:
Richar (OTA-I	d M. Scheffler and Morgan Delaney Bp-H-9(12))		A Clinical, Industrial, and Policy Analysis; Earl P. Steinberg and Alan Cohen (OTA-HCS-27
Effectiven	Radionuclide Imaging and Cost ess; n B. Stason and Eric Fortess	28	Intensive Care Units (ICUS): Clinical Outcomes, Costs, and Decisionmaking; Robert A. Berenson (OTA-HCS-28)
(OTA-l	BP-H-9(13)) efit/Cost Effectiveness of Medical	29	
Printing Office, V Information Serv	e by the Superintendent of Documents, U.S. Government Washington, D. C., 20402, and by the National Technical vice, 5285 Port Royal Road, Springfield, Va., 22161, Call g Office (224-8996) for availability and ordering infor-	Med 'Back Med	ckground paper #3 to The Implications of Cost-Effectiveness Analysis dical Technology. kground Paper #5 to The Implications of Cost-Effectiveness Analysis dical Technology. kground paper +1 to OTA'S Ma 1982 report Technology and Hang

Medical Technology. Background paper +1 to OTA'S Ma,1982 report Technology and Handi-OTA's Publishing Office (224-8996) for availability and ordering infor-mation. Original publication numbers appear in parentheses. The first 17 cases in the series were 17 separately issued cases in *Background Paper #2:* Case *Studies of Medical Technologies*, prepared in conjunction with OTA's August 1980 report 77re *Implications of Cost-Effectiveness* Anal-ysis of Medical Technology.

capped People. 8Background Paper #2 to Technolog, and Handicapped People.

### OTA Project Staff for Case Study #29

Roger Herdman<sup>1</sup> and H. David Banta,<sup>2</sup> Assistant Director, OTA Health and Life Sciences Division

Clyde J. Behney, Health Program Manager

Jane E. Sisk, *Project Director* Katherine E. Locke, *Research Assistant* H. Christy Bergemann, *Editor* 

Virginia Cwalina, Administrative Assistant Rebecca I. Erickson, Secretary/Word Processor Specialist Brenda Miller, Word Processor/P. C. Specialist

"From December 1983 "Until August 1983.

### Advisory Panel for Federal Policies and the Medical Devices Industry

Richard R. Nelson, *Chair* Institute for Social and Policy Studies, Yale University New Haven, CT

William F. Ballhaus International Numatics, Inc. Beverly Hills, CA

Ruth Farrisey Massachusetts General Hospital Boston, MA

Peter Barton Hutt Covington & Burling Washington, DC

Alan R. Kahn Consultant Cincinnati, OH

Grace Kraft Kidney Foundation of the Upper Midwest Cannon Falls, MN

Joyce Lashof School of Public Health University of California Berkelev, CA

Penn Lupovich Group Health Association Washington, DC

Victor McCoy Paralyzed Veterans of America Washington, DC Robert M. Moliter Medical Systems Division General Electric Co. Washington, DC

Louise B. Russell The Brookings Institution Washington, DC

Earl J. Saltzgiver Foremost Contact Lens Service, Inc. Salt Lake City, UT

Rosemary Stevens Department of History and Sociology of Science University of Pennsylvania Philadelphia, PA

Allan R. Thieme Amigo Sales, Inc. Albuquerque, NM

Eric von Hippel Sloan School Massachusetts Institute of Technology Cambridge, MA

Edwin C. Whitehead Technicon Corp. Tarrytown, NY